Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

NCT ID: NCT00925600

Last Updated: 2017-05-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

769 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2016-05-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Cataract Low Bone Mineral Density Osteopenia Osteoporosis Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Participants received placebo administered by subcutaneous injection on Day 1 and at Month 6.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Prefilled syringe for subcutaneous (SC) injection

Denosumab

Participants received denosumab 60 mg administered by subcutaneous injection on Day 1 and at Month 6.

Group Type EXPERIMENTAL

Denosumab

Intervention Type BIOLOGICAL

Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Denosumab

Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg

Intervention Type BIOLOGICAL

Placebo

Prefilled syringe for subcutaneous (SC) injection

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Prolia®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men ≥ 30 years of age with non-metastatic prostate cancer, having undergone bilateral orchiectomy or initiated androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists and is expected to continue on ADT for at least 12 months
* Adequate visual accuracy allowing eye testing
* Bone Mineral Density (BMD) requirements: Osteopenia if under 70 years of age; Osteopenia or normal BMD if over 70 years of age
* Signed informed consent

Exclusion Criteria

* Previous surgery for cataracts in both eyes, current diagnosis of cataracts, cataracts surgery foreseen in the near future, or ocular disease leading to visual loss
* Diagnosis of osteoporosis
Minimum Eligible Age

30 Years

Maximum Eligible Age

120 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amgen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MD

Role: STUDY_DIRECTOR

Amgen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Anaheim, California, United States

Site Status

Research Site

Laguna Hills, California, United States

Site Status

Research Site

Murrieta, California, United States

Site Status

Research Site

San Diego, California, United States

Site Status

Research Site

San Diego, California, United States

Site Status

Research Site

San Diego, California, United States

Site Status

Research Site

San Luis Obispo, California, United States

Site Status

Research Site

Denver, Colorado, United States

Site Status

Research Site

Denver, Colorado, United States

Site Status

Research Site

Englewood, Colorado, United States

Site Status

Research Site

Middlebury, Connecticut, United States

Site Status

Research Site

New Britain, Connecticut, United States

Site Status

Research Site

Trinity, Florida, United States

Site Status

Research Site

Coeur d'Alene, Idaho, United States

Site Status

Research Site

Greenwood, Indiana, United States

Site Status

Research Site

West Des Moines, Iowa, United States

Site Status

Research Site

Kansas City, Kansas, United States

Site Status

Research Site

Shreveport, Louisiana, United States

Site Status

Research Site

Annapolis, Maryland, United States

Site Status

Research Site

Baltimore, Maryland, United States

Site Status

Research Site

Greenbelt, Maryland, United States

Site Status

Research Site

Grand Rapids, Michigan, United States

Site Status

Research Site

Sartell, Minnesota, United States

Site Status

Research Site

St Louis, Missouri, United States

Site Status

Research Site

Missoula, Montana, United States

Site Status

Research Site

Omaha, Nebraska, United States

Site Status

Research Site

Omaha, Nebraska, United States

Site Status

Research Site

Berlin, New Jersey, United States

Site Status

Research Site

Brick, New Jersey, United States

Site Status

Research Site

Englewood, New Jersey, United States

Site Status

Research Site

Lawrenceville, New Jersey, United States

Site Status

Research Site

Mount Laurel, New Jersey, United States

Site Status

Research Site

Albany, New York, United States

Site Status

Research Site

Garden City, New York, United States

Site Status

Research Site

Kingston, New York, United States

Site Status

Research Site

New York, New York, United States

Site Status

Research Site

Poughkeepsie, New York, United States

Site Status

Research Site

Syracuse, New York, United States

Site Status

Research Site

Gastonia, North Carolina, United States

Site Status

Research Site

Greenville, North Carolina, United States

Site Status

Research Site

Cincinnati, Ohio, United States

Site Status

Research Site

Bala-Cynwyd, Pennsylvania, United States

Site Status

Research Site

Lancaster, Pennsylvania, United States

Site Status

Research Site

Philadelphia, Pennsylvania, United States

Site Status

Research Site

Myrtle Beach, South Carolina, United States

Site Status

Research Site

Knoxville, Tennessee, United States

Site Status

Research Site

Austin, Texas, United States

Site Status

Research Site

Dallas, Texas, United States

Site Status

Research Site

San Antonio, Texas, United States

Site Status

Research Site

Temple, Texas, United States

Site Status

Research Site

Richmond, Virginia, United States

Site Status

Research Site

Salem, Virginia, United States

Site Status

Research Site

Wahroonga, New South Wales, Australia

Site Status

Research Site

Herston, Queensland, Australia

Site Status

Research Site

Bentleigh East, Victoria, Australia

Site Status

Research Site

Ringwood East, Victoria, Australia

Site Status

Research Site

Pleven, , Bulgaria

Site Status

Research Site

Plovdiv, , Bulgaria

Site Status

Research Site

Sofia, , Bulgaria

Site Status

Research Site

Kelowna, British Columbia, Canada

Site Status

Research Site

Vancouver, British Columbia, Canada

Site Status

Research Site

Victoria, British Columbia, Canada

Site Status

Research Site

Victoria, British Columbia, Canada

Site Status

Research Site

Halifax, Nova Scotia, Canada

Site Status

Research Site

Barrie, Ontario, Canada

Site Status

Research Site

Brampton, Ontario, Canada

Site Status

Research Site

Brantford, Ontario, Canada

Site Status

Research Site

Burlington, Ontario, Canada

Site Status

Research Site

Guelph, Ontario, Canada

Site Status

Research Site

Kitchener, Ontario, Canada

Site Status

Research Site

London, Ontario, Canada

Site Status

Research Site

Newmarket, Ontario, Canada

Site Status

Research Site

North Bay, Ontario, Canada

Site Status

Research Site

North York, Ontario, Canada

Site Status

Research Site

Oakville, Ontario, Canada

Site Status

Research Site

Scarborough Village, Ontario, Canada

Site Status

Research Site

Toronto, Ontario, Canada

Site Status

Research Site

Toronto, Ontario, Canada

Site Status

Research Site

Toronto, Ontario, Canada

Site Status

Research Site

Laval, Quebec, Canada

Site Status

Research Site

Montreal, Quebec, Canada

Site Status

Research Site

Benešov, , Czechia

Site Status

Research Site

Brno, , Czechia

Site Status

Research Site

Hradec Králové, , Czechia

Site Status

Research Site

Jindřichův Hradec, , Czechia

Site Status

Research Site

Kroměříž, , Czechia

Site Status

Research Site

Nový Jičín, , Czechia

Site Status

Research Site

Olomouc, , Czechia

Site Status

Research Site

Pilsen, , Czechia

Site Status

Research Site

Prague, , Czechia

Site Status

Research Site

Prague, , Czechia

Site Status

Research Site

Prague, , Czechia

Site Status

Research Site

Ústí nad Labem, , Czechia

Site Status

Research Site

Zlín, , Czechia

Site Status

Research Site

Lyon Cédex 3, , France

Site Status

Research Site

Paris, , France

Site Status

Research Site

Alexandroupoli, , Greece

Site Status

Research Site

Athens, , Greece

Site Status

Research Site

Athens, , Greece

Site Status

Research Site

Athens, , Greece

Site Status

Research Site

Heraklion, , Greece

Site Status

Research Site

Larissa, , Greece

Site Status

Research Site

Pátrai, , Greece

Site Status

Research Site

Thessaloniki, , Greece

Site Status

Research Site

Thessaloniki, , Greece

Site Status

Research Site

Baja, , Hungary

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Győr, , Hungary

Site Status

Research Site

Miskolc, , Hungary

Site Status

Research Site

Nyíregyháza, , Hungary

Site Status

Research Site

Szeged, , Hungary

Site Status

Research Site

Ahmedabad, Gujarat, India

Site Status

Research Site

Bangalore, Karnataka, India

Site Status

Research Site

Aurangabad, Maharashtra, India

Site Status

Research Site

Nashik, Maharashtra, India

Site Status

Research Site

Ludhiana, Punjab, India

Site Status

Research Site

Madurai, Tamil Nadu, India

Site Status

Research Site

Kolkata, West Bengal, India

Site Status

Research Site

Jelgava, , Latvia

Site Status

Research Site

Riga, , Latvia

Site Status

Research Site

Riga, , Latvia

Site Status

Research Site

Distrito Federal, , Mexico

Site Status

Research Site

Distrito Federal, , Mexico

Site Status

Research Site

Christchurch, , New Zealand

Site Status

Research Site

Takapuna, North Shore City, , New Zealand

Site Status

Research Site

Tauranga, , New Zealand

Site Status

Research Site

Whangarei, , New Zealand

Site Status

Research Site

Gdansk, , Poland

Site Status

Research Site

Gdansk, , Poland

Site Status

Research Site

Gdynia, , Poland

Site Status

Research Site

Gdynia, , Poland

Site Status

Research Site

Katowice, , Poland

Site Status

Research Site

Mysłowice, , Poland

Site Status

Research Site

Opole, , Poland

Site Status

Research Site

Poznan, , Poland

Site Status

Research Site

Rzeszów, , Poland

Site Status

Research Site

Siedlce, , Poland

Site Status

Research Site

Szczecin, , Poland

Site Status

Research Site

Słupsk, , Poland

Site Status

Research Site

Warsaw, , Poland

Site Status

Research Site

Warsaw, , Poland

Site Status

Research Site

Warsaw, , Poland

Site Status

Research Site

Wroclaw, , Poland

Site Status

Research Site

Ivanovo, , Russia

Site Status

Research Site

Moscow, , Russia

Site Status

Research Site

Moscow, , Russia

Site Status

Research Site

Moscow, , Russia

Site Status

Research Site

Nizhny Novgorod, , Russia

Site Status

Research Site

Rostov-on-Don, , Russia

Site Status

Research Site

Bratislava, , Slovakia

Site Status

Research Site

Košice, , Slovakia

Site Status

Research Site

Košice, , Slovakia

Site Status

Research Site

Košice, , Slovakia

Site Status

Research Site

Martin, , Slovakia

Site Status

Research Site

Nitra, , Slovakia

Site Status

Research Site

Trenčín, , Slovakia

Site Status

Research Site

Celje, , Slovenia

Site Status

Research Site

Ljubljana, , Slovenia

Site Status

Research Site

Slovenj Gradec, , Slovenia

Site Status

Research Site

Paarl, Western Cape, South Africa

Site Status

Research Site

George, , South Africa

Site Status

Research Site

Kempton Park, , South Africa

Site Status

Research Site

Port Elizabeth, , South Africa

Site Status

Research Site

Tygerberg, , South Africa

Site Status

Research Site

Chernivtsi, , Ukraine

Site Status

Research Site

Dnipropetrovsk, , Ukraine

Site Status

Research Site

Kharkiv, , Ukraine

Site Status

Research Site

Kyiv, , Ukraine

Site Status

Research Site

Uzhhorod, , Ukraine

Site Status

Research Site

Zaporizhzhya, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Bulgaria Canada Czechia France Greece Hungary India Latvia Mexico New Zealand Poland Russia Slovakia Slovenia South Africa Ukraine

Related Links

Access external resources that provide additional context or updates about the study.

http://www.amgentrials.com

AmgenTrials clinical trials website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2009-012076-26

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

20080560

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Osteoclast Inhibition and Bone Formation
NCT02554695 COMPLETED EARLY_PHASE1
Denosumab China Phase III Study
NCT02014467 COMPLETED PHASE3